Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024 These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerl...
Novartis Global Health & Sustainability aims to transform health in lower income populations through applying expertise, people and full organizational capability to address major, unresolved global health challenges. Malaria is part of the Novartis Global Health & Sustainability Unit. For more than 20 ...
Novartis in Society Integrated Report ESG rating performance Targets Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance Lear...
Malaria is part of the Novartis Global Health & Sustainability Unit. For more than 20 years, Novartis has been working with partners around the world to eliminate malaria. Since 2000, we have delivered more than 1 billion treatment courses of our antimalarial, including more than 470 million ...
nvsef news novartis pulls back after report on emasan share offering sa news tue, feb. 25 novartis ag 2024 q4 - results - earnings call presentation fri, jan. 31 earnings call insights novartis targets 5%+ annual sales growth through 2029 amid robust brand performance sa insights fri, jan....